1. Metabolic Enzyme/Protease Cell Cycle/DNA Damage
  2. PDHK HSP
  3. PDK-IN-1

PDK-IN-1 (compound 7o) is a pyruvate dehydrogenase kinase (PDK) inhibitor. PDK-IN-1 shows IC50 values of 0.03 and 0.1 μM for PDK1 and HSP90, respectively. PDK-IN-1 targets PDH/PDK axis thus reducing efficiently the tumor mass.

For research use only. We do not sell to patients.

PDK-IN-1 Chemical Structure

PDK-IN-1 Chemical Structure

CAS No. : 2897696-10-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products

View All HSP Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PDK-IN-1 (compound 7o) is a pyruvate dehydrogenase kinase (PDK) inhibitor. PDK-IN-1 shows IC50 values of 0.03 and 0.1 μM for PDK1 and HSP90, respectively. PDK-IN-1 targets PDH/PDK axis thus reducing efficiently the tumor mass[1].

IC50 & Target

IC50: 0.03 ± 0.005 μM (PDK1); 0.1 μM (HSP90)[1]

In Vitro

PDK-IN-1 (compound 7o) shows 2D cytotoxic activity against PSN-1 and BxPC-3 pancreatic cell lines, with IC50 values of 0.1 ± 0.04 and 1.0 ± 0.2 μM, respectively. PDK-IN-1 also shows 3D cytotoxic activity, with IC50 values of 3.3 ± 0.2 and 11.9 ± 1.1 μM, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PDK-IN-1 (compound 7o) is slightly more effective than cisplatin (HY-17394) in reducing the tumor mass[1].
PDK-IN-1 intensely reduces PDH phosphorylation in Lewis Lung Carcinoma (LLC)-bearing mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: LLC-bearing C57BL mice[1]
Dosage: 20 mg/kg
Administration: IP, daily, days 7-14
Result: Reduced more tumor mass than cisplatin (HY-17394) (tumor inhibition by 86 and 84% for compound 7o and cisplatin, respectively). Induced a body weight loss much lower than that induced by cisplatin (HY-17394) and gemcitabine (HY-17026).
Molecular Weight

450.29

Formula

C20H16BrN7O

CAS No.
SMILES

BrC1=CC(C(C2=C(C3=CNC4=C3C=C(OC)C=C4)N=NC(N)=N2)=CN5C)=C5N=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PDK-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PDK-IN-1
Cat. No.:
HY-149814
Quantity:
MCE Japan Authorized Agent: